NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide

Description

NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. Offer reference number: CM/PHG/24/5716 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Periods of call-offs under the framework agreement: CM/PHG/24/5716/01– NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028 NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028 LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028